Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

The MPN PROGRESSion Registry: A Retrospective and Prospective Observational Study Collecting Patient-Reported Outcomes, Electronic Health Records, and Claims Data to Track Symptoms, Treatments, and Disease Progression in Individuals Diagnosed With Myeloproliferative Neoplasms (MPNs).

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT07362225
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:34.413923+00:00
Published At
2026-01-23T00:00:00+00:00
Record Updated At
2026-01-23
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Polycythemia Vera", "ET (Essential Thrombocythemia)", "Polycythemia Vera (PV)", "Essential Thrombocythemia (ET)", "Primary Myelofibrosis (MF)", "Primary Myelofibrosis (PMF)", "Myelofibrosis", "Myelofibrosis (MF)", "Myelofibrosis, Primary", "Myelofibrosis, Post ET", "Myelofibrosis, Post PV", "Myelofibrosis (PMF)", "Myelofibrosis\uff0cMF", "Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis", "Myelofibrosis Due to and Following Polycythemia Vera", "Myelofibrosis Transformation in Essential Thrombocythemia", "Myelofibrosis With High Molecular Risk Mutations", "MF", "Secondary Myelofibrosis", "Secondary Myelofibrosis in Myeloproliferative Disease", "Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)", "Post-Polycythemia Vera Myelofibrosis", "Post-polycythemia Vera Myelofibrosis (PPV-MF)", "Post-polycythemia Vera Myelofibrosis (Post-PV MF)", "Post-polycythemia Vera Myelofibrosis(Post-PV MF)", "Post-PV MF", "Post-Essential Thrombocythemia Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis (PET-MF)", "Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)", "Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)", "Post-ET MF", "Pre-fibrotic Myelofibrosis", "Myeloproliferative Disorder", "Myeloproliferative Disorders", "Myeloproliferative Disorders (MPD)", "Myeloproliferative Neoplasms (MPNs)", "Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis", "Myeloproliferative Neoplasm With 10% Blasts or Higher", "Myeloproliferative Neoplasms", "MPN", "MPN (Myeloproliferative Neoplasms)", "MPN-associated Myelofibrosis", "Myeloproliferative Neoplasm, Unclassifiable", "Myeloproliferative Neoplasm, Not Otherwise Specified", "Accelerated Phase MPN", "Accelerated Phase Myeloproliferative Neoplasm", "Blast Phase MPN", "Blast Phase Myeloproliferative Neoplasm", "Thrombocythemia Myelofibrosis (PET-MF)", "Thrombocythemia, Essential", "Thrombocythemia, Hemorrhagic", "Agnogenic Myeloid Metaplasia", "Chronic Idiopathic Myelofibrosis", "Idiopathic Myelofibrosis", "MDS/MPN Crossover Syndromes"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-01-23"
protocolSection.identificationModule.nctId
"NCT07362225"
protocolSection.identificationModule.officialTitle
"The MPN PROGRESSion Registry: A Retrospective and Prospective Observational Study Collecting Patient-Reported Outcomes, Electronic Health Records, and Claims Data to Track Symptoms, Treatments, and Disease Progression in Individuals Diagnosed With Myeloproliferative Neoplasms (MPNs)."
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
[]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Polycythemia Vera (protocolSection.conditionsModule.conditions)
  • ET (Essential Thrombocythemia) (protocolSection.conditionsModule.conditions)
  • Polycythemia Vera (PV) (protocolSection.conditionsModule.conditions)
  • Essential Thrombocythemia (ET) (protocolSection.conditionsModule.conditions)
  • Primary Myelofibrosis (MF) (protocolSection.conditionsModule.conditions)
  • Primary Myelofibrosis (PMF) (protocolSection.conditionsModule.conditions)
  • Myelofibrosis (protocolSection.conditionsModule.conditions)
  • Myelofibrosis (MF) (protocolSection.conditionsModule.conditions)
  • Myelofibrosis, Primary (protocolSection.conditionsModule.conditions)
  • Myelofibrosis, Post ET (protocolSection.conditionsModule.conditions)
  • Myelofibrosis, Post PV (protocolSection.conditionsModule.conditions)
  • Myelofibrosis (PMF) (protocolSection.conditionsModule.conditions)
  • Myelofibrosis，MF (protocolSection.conditionsModule.conditions)
  • Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis (protocolSection.conditionsModule.conditions)
  • Myelofibrosis Due to and Following Polycythemia Vera (protocolSection.conditionsModule.conditions)
  • Myelofibrosis Transformation in Essential Thrombocythemia (protocolSection.conditionsModule.conditions)
  • Myelofibrosis With High Molecular Risk Mutations (protocolSection.conditionsModule.conditions)
  • MF (protocolSection.conditionsModule.conditions)
  • Secondary Myelofibrosis (protocolSection.conditionsModule.conditions)
  • Secondary Myelofibrosis in Myeloproliferative Disease (protocolSection.conditionsModule.conditions)
  • Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis) (protocolSection.conditionsModule.conditions)
  • Post-Polycythemia Vera Myelofibrosis (protocolSection.conditionsModule.conditions)
  • Post-polycythemia Vera Myelofibrosis (PPV-MF) (protocolSection.conditionsModule.conditions)
  • Post-polycythemia Vera Myelofibrosis (Post-PV MF) (protocolSection.conditionsModule.conditions)
  • Post-polycythemia Vera Myelofibrosis(Post-PV MF) (protocolSection.conditionsModule.conditions)
  • Post-PV MF (protocolSection.conditionsModule.conditions)
  • Post-Essential Thrombocythemia Myelofibrosis (protocolSection.conditionsModule.conditions)
  • Post-essential Thrombocythemia Myelofibrosis (PET-MF) (protocolSection.conditionsModule.conditions)
  • Post-essential Thrombocythemia Myelofibrosis(Post-ET MF) (protocolSection.conditionsModule.conditions)
  • Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) (protocolSection.conditionsModule.conditions)
  • Post-ET MF (protocolSection.conditionsModule.conditions)
  • Pre-fibrotic Myelofibrosis (protocolSection.conditionsModule.conditions)
  • Myeloproliferative Disorder (protocolSection.conditionsModule.conditions)
  • Myeloproliferative Disorders (protocolSection.conditionsModule.conditions)
  • Myeloproliferative Disorders (MPD) (protocolSection.conditionsModule.conditions)
  • Myeloproliferative Neoplasms (MPNs) (protocolSection.conditionsModule.conditions)
  • Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis (protocolSection.conditionsModule.conditions)
  • Myeloproliferative Neoplasm With 10% Blasts or Higher (protocolSection.conditionsModule.conditions)
  • Myeloproliferative Neoplasms (protocolSection.conditionsModule.conditions)
  • MPN (protocolSection.conditionsModule.conditions)
  • MPN (Myeloproliferative Neoplasms) (protocolSection.conditionsModule.conditions)
  • MPN-associated Myelofibrosis (protocolSection.conditionsModule.conditions)
  • Myeloproliferative Neoplasm, Unclassifiable (protocolSection.conditionsModule.conditions)
  • Myeloproliferative Neoplasm, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
  • Accelerated Phase MPN (protocolSection.conditionsModule.conditions)
  • Accelerated Phase Myeloproliferative Neoplasm (protocolSection.conditionsModule.conditions)
  • Blast Phase MPN (protocolSection.conditionsModule.conditions)
  • Blast Phase Myeloproliferative Neoplasm (protocolSection.conditionsModule.conditions)
  • Thrombocythemia Myelofibrosis (PET-MF) (protocolSection.conditionsModule.conditions)
  • Thrombocythemia, Essential (protocolSection.conditionsModule.conditions)
  • Thrombocythemia, Hemorrhagic (protocolSection.conditionsModule.conditions)
  • Agnogenic Myeloid Metaplasia (protocolSection.conditionsModule.conditions)
  • Chronic Idiopathic Myelofibrosis (protocolSection.conditionsModule.conditions)
  • Idiopathic Myelofibrosis (protocolSection.conditionsModule.conditions)
  • MDS/MPN Crossover Syndromes (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.